来自全球100多家制药和生物技术公司
2005年以来，我们一直在俄罗斯、中东欧国家及欧洲，为全球制药和生物技术客户管理临床试验。
We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
2005年以来，我们一直在俄罗斯、中东欧国家及欧洲，为全球制药和生物技术客户管理临床试验。
十多年来，我们始终为得到申办者的信任而无比自豪，也时刻保持谦卑。我们提供的全方位CRO服务，帮助全球申办者进行临床试验外包，并将他们的创新疗法推向市场。
我们的申办者来自世界各地的制药和生物技术公司。
我们很高兴OCT Clinical能够在规定时间内，满足我们的招募需求，特别是在夏季的时候。
We're pleased with the OCT team for having successfully completed our study and achieving patient recruitment target ahead of the schedule.
We are very pleased with the OCT Clinical team for meeting our recruitment goal under such difficult conditions. The achievement is quite impressive, considering the challenging circumstances imposed by the global pandemic.
We are happy with the results OCT Clinical has been demonstrating as the principal CRO for the project.
We are pleased to once again work with the professional OCT Clinical team as we continue to generate important scientific evidence related to our MED3000 gel.
如需查看推荐信和我们目前的客户名单，请联系info@oct-clinicaltrials.com
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.